Effect of Liraglutide on Vascular Inflammation in Type-2 Diabetes

NCT03449654 on ClinicalTrials.gov · last registry update 2020-06-11

Finished 16 August 2019, after enrolling 102 people. Primary outcome, as filed: Change in vascular inflammation. liraglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P4
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: Steno Diabetes Center Copenhagen
Sponsor type: Other
Enrollment: 102
Started: 2017-10-26
Primary completion: 2019-08-16 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change in vascular inflammation

Conditions studied

Diabetes Mellitus, Type 2

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.